How to Verify a GLP-1 Website Before Sharing Health Info

Start by identifying what kind of site you are actually on

Before you share health information, figure out whether the site is acting as a referral layer, a telehealth provider, a pharmacy-adjacent brand, or something less clear. That distinction matters because it changes what the site can legitimately promise and what it should disclose before you click deeper.

A trustworthy site makes that role visible early. If you have to infer who reviews eligibility, who prescribes, or who ships medication, the page is asking you to trust too much before you have enough facts.

The first trust checks to run before you touch the form

• Can you find privacy, terms, and contact information without digging?
• Does the page explain who reviews medical fit and whether approval is conditional?
• Is the provider or pharmacy boundary described in plain language?
• Are refund, cancellation, or support expectations visible before the click?
• Does the site disclose when it may receive compensation for referrals?

Why compounded GLP-1 pages need extra caution

FDA guidance makes this simple: compounded GLP-1 drugs are not FDA approved, and consumers should be careful about sourcing, shipping quality, and how products are described online. That does not tell you which specific path is right for you, but it does tell you to read the page more carefully before treating it like ordinary ecommerce.

In practical terms, that means checking how the site talks about prescribing, pharmacy handling, storage, and what happens if a product or delivery issue comes up later.

Sources: [1] [3]

What good language usually sounds like

Conditional language is not weak marketing. It is usually the clearest sign that the page understands the clinical boundary instead of trying to hide it.

• Reviewed by a licensed provider.
• Prescription only if clinically appropriate.
• Dispensed or fulfilled through a licensed pharmacy workflow.
• Additional questions or follow-up may be needed before a decision is made.

When to stop and not submit yet

Pause when the site sounds like approval is assumed, when policy pages are hard to find, when sourcing language is vague, or when you still cannot tell who is responsible for which step in the process. Those gaps matter more than convenience in a health-related funnel.

The best time to slow down is before you have shared anything personal, not after.

Where this fits inside DirectMeds

DirectMeds is strongest when readers use its public pages to understand the referral model and the two featured medication paths before they move into a partner intake. That makes the site easier to evaluate because the trust question comes before the click, not after it.

If the trust signals hold up, the next step is to compare the semaglutide and tirzepatide pages directly. If they do not, the right move is to keep reading, not rush.